Table 3.
Immunoreactivitya | 0% | ≤50% | >50% | t-test |
---|---|---|---|---|
p63 in normal ductsb | 0 | 0 | 100% | |
p63 in DCIS | 4% | 52% | 44% | p=.01 |
CD31 in normal vessels | 0 | 0 | 100% | |
CD31 in LVI | 75% | 20% | 5% | p=.01 |
D2-40c in normal lymphatics | 0 | 0 | 100% | |
D2-40 in LVI | 55% | 34% | 11% | p=.01 |
p63 in normal vessels/lymphatics | 100% | 0% | 0% | |
p63 in LVI | 97% | Occasional cells | 0% | p=.05 |
p63/CD31 in normal vessels | 100% | 0 | 0 | |
p63/CD31 in LVI | 95% | Occasional cells | 0% | p=.05 |
p63/D2-40 in normal lymphatics | 100% | 0 | 0 | |
p63/D2-40 in LVI | 97% | Occasional cells | 0% | p=.05 |
A total of 100 ducts, lymphatics and blood vessels were separately counted. Immunoreactivity around these ducts and vessels is recorded as a percentage of circumferential immunoreactivity.
Immunoreactivity for the designated marker(s) is recorded as percentage of 100 structures showing the indicated degree of circumferential immunoreactivity.
The distribution of two other lymphatic endothelial markers, nuclear Prox-1 and cytoplasmic/membrane VEGFR-3 was similar to D2-40 (p=0.1).